{Reference Type}: Journal Article
{Title}: Whither CAR T? will the FDA being under the hood and the availability of bispecifics make these therapies less attractive?
{Author}: Chao S;Tse J;VanGalder A;Wong G;Wonsettler T;Hertler A;
{Journal}: Am J Manag Care
{Volume}: 30
{Issue}: 7
{Year}: 2024 Jun
{Factor}: 3.247
{DOI}: 10.37765/ajmc.2024.89576